Lifecore Biomedical, Inc., an integrated CDMO, has signed an agreement with a leading global pharmaceutical company. Under the agreement, Lifecore will transfer the commercial manufacturing for a leading injectable pharmaceutical product from the current manufacturer to Lifecore’s facilities. Upon completion of the transfer and satisfaction of all regulatory requirements, Lifecore will be the commercial supplier of choice for the product. 

This is the second agreement that Lifecore has signed with the same multinational organization in recent months.

“This commercial site transfer is a significant accomplishment in our ongoing growth strategy as we work to expand our CDMO business and build long-term partnerships with leading global pharmaceutical companies. Importantly, this product will broaden our commercial customer base while also allowing us to increase our capacity utilization and expand into new modalities,” said Paul Josephs, chief executive officer of Lifecore. 

In additional business development news, Lifecore also announced the signing of a separate agreement with an early-stage biotechnology company to provide pre-clinical formulation development services. This new customer addition continues to grow the company’s early-stage program pipeline, addressing another one of Lifecore’s three growth strategies.

Lifecore, PolyPeptide Partner on Peptide Manufacturing for U.S. Market